OSK1 peptide analogs and pharmaceutical compositions

• US 7,803,769 B2
• Filed: 10/25/2007
• Issued: 09/28/2010
• Est. Priority Date: 10/25/2006
• Status: Expired due to Fees

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Miranda, Leslie P., McGivern, Joseph G., Sullivan, John K.
• Primary Examiner(s): Romeo; David S
• Application Number:
  US11/978,110
• Publication Number:
  US 20090281028A1
• Time in Patent Office: 1,069 Days
• Field of Search: None
• US Class Current: 514/17.4
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/43522 from scorpions
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/31 fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

Claims

1. An OSK1 peptide analog comprising the amino acid sequence of SEQ ID NO:

4916, or a pharmaceutically acceptable salt of the OSK1 peptide analog.

2. The OSK1 peptide analog of claim 1, wherein the C-terminal carboxylic acid moiety is replaced with a moiety selected from

(A) —

COOR, where R is independently (C₁-C₈)alkyl, haloalkyl, aryl or heteroaryl;

(B) —

C(═

O)NRR, where R is independently hydrogen, (C₁-C₈)alkyl, haloalkyl, aryl or heteroaryl; and

(C) —

CH₂OR where R is hydrogen, (C₁-C₈)alkyl, aryl or heteroaryl.

3. A pharmaceutical composition, comprising the OSK1 peptide analog of claim 1, or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable carrier.